Digitek Recall due to risk of Digitalis Toxicity
Last week Actavis Totowa announced a nationwide Digitek recall due to manufacturing defects which caused some of the digoxin tablets to contain double the appropriate amount of active ingredients. This could lead to a substantial risk of a serious and potentially fatal illness, known as digitalis toxicity, especially among those with renal failure. The lawyers at Saiontz & Kirk, P.A. are reviewing potential Digitek recall lawsuits throughout the United States.
Digitek (digoxin) is a medication approved to treat heart failure and abnormal heart rhythms. The Digitek recall applies to about half of the digoxin supply in the United States. The tablets, which were manufactured by a division of Actavis Group, were distrubted by Mylan Pharmaceuticals, Inc. and UDL Laboratories,Inc. under the labels “Bertek Digitek” and “UDL Digitek”.
The Digitek recall was initiated after Actavis received a number of reports of severe illness, known as digitalis toxicity. According to some reports, the manufacturer began receiving notice as early as 2006 about potential Digitek side effects which could have been associated with twice the active ingredient being contained in the tablets.
Digitalis toxicity is a serious and potentially fatal illness which is known to occur in people with impaired kidney function, particularly those with renal failure. It is caused by excessive amounts of digitalis accumulating in the body. Symptoms of Digitalis Toxicity include:
- Low Blood Pressure
- Cardiac Instability
DIGITEK RECALL LAWYERS
The recall lawyers at Saiontz & Kirk, P.A. are investigating potential Digitex lawsuits on behalf of users of the medication who have required medical treatment as a result of digitalis toxicity. If you, a friend or family member have experienced Digitek problems, request a free consultation and claim evaluation.